Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]

Affiliations

¹ Institute Gustave Roussy, Villejuif, France. Electronic address: escudier@gustaveroussy.fr.
² MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
³ Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
⁴ Roswell Park Cancer Institute, Buffalo, NY, USA.
⁵ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
⁶ Stanford Cancer Institute, Stanford, CA, USA.
⁷ University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁸ Vanderbilt University Medical Center, Nashville, TN, USA.
⁹ Fondazione Istituto Nazionale Tumori, Milan, Italy.
¹⁰ Fox Chase Cancer Center, Philadelphia, PA, USA.
¹¹ Hospital Universitario 12 De Octubre, Madrid, Spain.
¹² Westmead Hospital, Westmead, NSW, Australia.
¹³ Aarhus University Hospital, Aarhus, Denmark.
¹⁴ Comprehensive Cancer Center, Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
¹⁵ South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK.
¹⁶ University Hospital Essen of University of Duisburg-Essen, Essen, Germany.
¹⁷ Chiba Cancer Center, Chiba, Japan.
¹⁸ Bristol-Myers Squibb, Princeton, NJ, USA.
¹⁹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Published Erratum

Bernard Escudier et al. Eur Urol. 2018 Apr.

. 2018 Apr;73(4):e116-e118.

doi: 10.1016/j.eururo.2017.12.016. Epub 2018 Jan 3.

¹ Institute Gustave Roussy, Villejuif, France. Electronic address: escudier@gustaveroussy.fr.
² MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
³ Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
⁴ Roswell Park Cancer Institute, Buffalo, NY, USA.
⁵ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
⁶ Stanford Cancer Institute, Stanford, CA, USA.
⁷ University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁸ Vanderbilt University Medical Center, Nashville, TN, USA.
⁹ Fondazione Istituto Nazionale Tumori, Milan, Italy.
¹⁰ Fox Chase Cancer Center, Philadelphia, PA, USA.
¹¹ Hospital Universitario 12 De Octubre, Madrid, Spain.
¹² Westmead Hospital, Westmead, NSW, Australia.
¹³ Aarhus University Hospital, Aarhus, Denmark.
¹⁴ Comprehensive Cancer Center, Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
¹⁵ South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK.
¹⁶ University Hospital Essen of University of Duisburg-Essen, Essen, Germany.
¹⁷ Chiba Cancer Center, Chiba, Japan.
¹⁸ Bristol-Myers Squibb, Princeton, NJ, USA.
¹⁹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.

No abstract available

Erratum for

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators. Escudier B, et al. Eur Urol. 2017 Dec;72(6):962-971. doi: 10.1016/j.eururo.2017.02.010. Epub 2017 Mar 3. Eur Urol. 2017. PMID: 28262413 Clinical Trial.